The 2012 Hormone Therapy Position Statement of The North American Menopause Society
Top Cited Papers
- 1 March 2012
- journal article
- practice guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in Menopause
- Vol. 19 (3), 257-271
- https://doi.org/10.1097/gme.0b013e31824b970a
Abstract
Objective This position statement aimed to update the evidence-based position statement published by The North American Menopause Society (NAMS) in 2010 regarding recommendations for hormone therapy (HT) for postmenopausal women. This updated position statement further distinguishes the emerging differences in the therapeutic benefit-risk ratio between estrogen therapy (ET) and combined estrogen-progestogen therapy (EPT) at various ages and time intervals since menopause onset. Methods An Advisory Panel of expert clinicians and researchers in the field of women’s health was enlisted to review the 2010 NAMS position statement, evaluate new evidence, and reach consensus on recommendations. The Panel’s recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. Results Current evidence supports the use of HT for perimenopausal and postmenopausal women when the balance of potential benefits and risks is favorable for the individual woman. This position statement reviews the effects of ET and EPT on many aspects of women’s health and recognizes the greater safety profile associated with ET. Conclusions Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms and to prevent osteoporosis in women at high risk of fracture. The more favorable benefit-risk ratio for ET allows more flexibility in extending the duration of use compared with EPT, where the earlier appearance of increased breast cancer risk precludes a recommendation for use beyond 3 to 5 years.Keywords
This publication has 135 references indexed in Scilit:
- Stroke risk in women: the role of menopause and hormone therapyThe Lancet Neurology, 2012
- Hip fracture in postmenopausal women after cessation of hormone therapyMenopause, 2011
- Paradoxical Clinical Effect of Estrogen on Breast Cancer Risk: A “New” Biology of Estrogen-induced ApoptosisCancer Prevention Research, 2011
- EndometriosisThe New England Journal of Medicine, 2010
- Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysisBMJ, 2008
- Brief report: Coronary heart disease events associated with hormone therapy in younger and older womenJournal of General Internal Medicine, 2006
- Calcium plus Vitamin D Supplementation and the Risk of FracturesThe New England Journal of Medicine, 2006
- Effects of Estrogen With and Without Progestin on Urinary IncontinenceJAMA, 2005
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998